Financial Performance - In 2022, the company's operating revenue was RMB 4,175.28 million, an increase of 10.06% compared to RMB 3,793.62 million in 2021[8]. - The net profit for 2022 was RMB 90.38 million, a significant increase of 290.36% from RMB 23.15 million in 2021[8]. - The basic and diluted earnings per share for 2022 were RMB 0.8369, compared to RMB 0.2144 in 2021[8]. - The total operating costs for 2022 were RMB 4,113.29 million, up from RMB 3,759.19 million in 2021[10]. - The total comprehensive income for the year ended December 31, 2022, was RMB 90,380,338.77, a significant increase from RMB 23,153,060.07 in 2021, representing a growth of approximately 289.5%[18]. - The gross profit increased by 14.56% to RMB 271.76 million for the year ended December 31, 2022, up from RMB 237.22 million for the previous year, with a gross margin rising from 6.25% to 6.51%[157]. - The total consolidated profit for the year amounted to RMB 122,053,698.11, with income tax expenses of RMB 31,673,359.34[72]. Assets and Liabilities - The total assets as of December 31, 2022, amounted to RMB 2,865.89 million, compared to RMB 2,763.09 million at the end of 2021[12]. - The total liabilities as of December 31, 2022, were RMB 2,271.40 million, slightly up from RMB 2,258.99 million in 2021[13]. - The company's total equity attributable to shareholders increased to RMB 594.48 million from RMB 504.10 million in 2021[13]. - The accounts receivable balance at year-end was RMB 865.01 million, up from RMB 745.19 million at the beginning of the year, reflecting a significant increase[40]. - The accounts payable increased to RMB 632,791,945.43 at the end of 2022, compared to RMB 532,860,284.07 at the beginning of the year, marking an increase of about 18.7%[31]. - The company's accounts payable as of December 31, 2022, included bank acceptance bills totaling RMB 876,775,586.87, an increase from RMB 809,768,308.81 at the beginning of the year[75]. Cash Flow and Dividends - The cash and cash equivalents decreased to RMB 492.67 million from RMB 630.17 million in 2021[12]. - The company proposed a final dividend of RMB 0.45 per share for the year ended December 31, 2022[8]. - The company plans to distribute a final dividend of RMB 0.45 per share for the year ended December 31, 2022, pending shareholder approval[74]. Operational Efficiency and Strategy - The company’s strategic focus on enhancing operational efficiency and competitive strength is expected to drive high-quality development in the future[24]. - The company aims to enhance customer loyalty by optimizing product structure and introducing high-margin quality products[55]. - The company is focusing on digital transformation and business innovation to improve supply chain efficiency and customer service experience[110]. - The company is exploring the feasibility of "Internet + Medicine" to enhance service capabilities and improve supply chain product flow[124]. - The company aims to expand its distribution network in Guangdong and surrounding areas, enhancing coverage for retail pharmacies and healthcare service institutions[107]. Market Trends and Industry Insights - In 2022, China's pharmaceutical distribution market sales reached RMB 866.7 billion, showing a year-on-year growth of 3.3%[34]. - The pharmaceutical wholesale market sales in 2021 were RMB 206.15 billion, with a year-on-year increase of 8.5%, marking a 6.1 percentage point rise in growth rate[34]. - By 2025, the goal is to cultivate 1-3 large digital and comprehensive pharmaceutical distribution companies with revenues exceeding RMB 500 billion, and 5-10 companies with revenues exceeding RMB 100 billion[35]. - The top 100 pharmaceutical distribution companies accounted for 98% of the national pharmaceutical market size in 2025, indicating a trend towards increased market concentration[35]. - The outpatient market is projected to reach RMB 1.6 trillion by 2029, potentially matching or exceeding the inpatient market[46]. Regulatory and Compliance - The implementation of new quality management standards for drug retail distribution starting January 1, 2023, aims to enhance quality control and traceability in the distribution process[38]. - The implementation of the "Regulations on the Supervision and Management of Online Drug Sales" began on December 1, 2022, allowing prescription drugs to be sold online[47]. - The Guangdong Provincial Drug Administration initiated a pilot program for large chain convenience stores to sell Class B non-prescription drugs starting in March 2022[50]. - The "Healthy China" initiative emphasizes comprehensive health services throughout the life cycle, promoting the integration of prevention, treatment, rehabilitation, and health management[52]. Human Resources and Compensation - The company reported a significant increase in employee compensation payable, which rose to RMB 13,346,444.66 from RMB 5,180,138.03 in the previous year, an increase of approximately 157.5%[20]. - The total employee cost, including directors' remuneration, was RMB 839.2 million, an increase of 11.91% from RMB 749.9 million in the previous year[165]. Logistics and Supply Chain - The company has actively expanded third-party logistics to enhance profitability and operational efficiency[42]. - The company plans to enhance its pharmaceutical logistics capabilities and actively expand third-party logistics services[153]. - The company's logistics network and information systems are designed to meet the growing demand for storage and logistics in the pharmaceutical distribution business[57]. Corporate Governance - The company has complied with the corporate governance code as per the listing rules, with exceptions noted regarding the standards for securities trading by directors and supervisors[184]. - The audit committee, along with the management and external auditors, reviewed the accounting principles and policies adopted by the group for the year ended December 31, 2022[187].

Company Performance - Operating revenue for the first half of 2022 was RMB 1,887,079, a decrease of 5.32% compared to RMB 1,993,014 in the same period of 2021[23]. - Total profit for the first half of 2022 was RMB 25,848, down 25.14% from RMB 34,530 in the first half of 2021[23]. - Net profit attributable to the shareholders of the parent company was RMB 20,639, reflecting a decline of 20.50% from RMB 25,961 in the same period of 2021[23]. - Basic and diluted earnings per share decreased to RMB 0.1911, down 20.50% from RMB 0.2404 in the first half of 2021[23]. - Operating revenue decreased by 5.32% to RMB 1,887.08 million for the six months ended June 30, 2022, compared to RMB 1,993.01 million for the same period in 2021[79]. - Revenue from principal business was RMB 1,868.01 million for the six months ended June 30, 2022, down from RMB 1,978.11 million in the same period of 2021[76]. - Gross profit decreased by 7.90% to RMB 124.37 million for the six months ended June 30, 2022, with a gross profit margin of 6.59%, down from 6.78% in the previous year[79]. - The Group's net profit decreased by 20.50% to RMB 20.64 million for the six months ended 30 June 2022 from RMB 25.96 million for the same period in 2021[87]. Financial Position - Total assets as of June 30, 2022, were RMB 2,646,289, a decrease of 4.23% from RMB 2,763,092 as of December 31, 2021[23]. - Total liabilities decreased by 6.08% to RMB 2,121,548 as of June 30, 2022, compared to RMB 2,258,990 as of December 31, 2021[23]. - Equity of shareholders increased by 4.09% to RMB 524,741 as of June 30, 2022, from RMB 504,102 as of December 31, 2021[23]. - As of June 30, 2022, the Group's cash and bank deposits amounted to RMB 67.98 million, down from RMB 144.23 million as of 31 December 2021[88]. - The Group recorded net current assets of RMB 98.68 million as of June 30, 2022, compared to RMB 79.30 million as of December 31, 2021[89]. - The current ratio was 1.05 as of June 30, 2022, slightly up from 1.04 as of December 31, 2021[89]. - Total current assets decreased to $2,137,774,795.80 from $2,238,222,282.83, a decline of approximately 4.5% year-over-year[164]. - Total liabilities decreased to $2,121,547,788.98 from $2,258,989,542.23, a reduction of approximately 6.1% year-over-year[166]. - Total shareholders' equity attributable to the shareholders of the parent company increased to $524,741,306.76 from $504,101,979.63, representing a growth of about 4.3%[169]. Market Trends and Industry Insights - The pharmaceutical distribution industry is expected to see the top 100 wholesale enterprises account for over 98% of the total market by 2025, indicating a trend towards market concentration[28]. - The government is promoting high-quality development in the pharmaceutical industry, with a focus on innovation and technology empowerment[28]. - The overall drug regulatory capability is projected to approach international advanced levels by the end of the "14th Five-Year Plan" period[28]. - The establishment of electronic prescription centers in Shenzhen and Hainan is expected to significantly influence the flow of prescription drugs in the regional market[35]. - The separation of prescribing and dispensing is becoming a general trend, driven by policies such as zero-markup drug policy and dual channels[35]. - The pharmaceutical retail chain industry in Guangdong is undergoing accelerated development, with support for independent pharmacies to join chain enterprises[39]. - The deepening of medical reform is expected to bring considerable increases in drug orders and overall growth in the pharmaceutical retail industry[35]. - By 2025, the annual sales of the top 100 pharmaceutical retail enterprises are expected to account for over 65% of the total pharmaceutical retail market, with a target retail chain rate approaching 70%[42]. Operational Efficiency and Logistics - The company has established logistics centers in Shantou, Foshan, Zhuhai, Guangzhou, and Huizhou, implementing an efficient delivery mechanism[8]. - The company has a modern information system covering the entire pharmaceutical distribution supply chain, including procurement, sales, warehousing, transportation, and delivery[8]. - The company has a professional transportation team that ensures timely deliveries within specified distances[8]. - The logistics network includes a core warehouse in Guangzhou, enabling multi-warehouse collaboration and improved inventory and distribution efficiency[57]. - The company has actively expanded third-party logistics services, generating additional revenue and enhancing profitability[59]. - The company aims to improve pharmaceutical supply chain operational efficiency and replicate mature non-tendering market operation models[72]. - The company will explore smart logistics technology applications to enhance delivery service capabilities and overall operational capacity[72]. - The pharmaceutical distribution industry is undergoing digital transformation, focusing on intelligent and automated logistics technology[48]. Corporate Governance and Compliance - The company has complied with the corporate governance code provisions as of June 30, 2022, with a noted deviation regarding the separation of roles between the chairman and CEO[126]. - The company will continue to review its corporate governance practices to enhance standards and comply with regulatory requirements[132]. - All directors and supervisors confirmed compliance with the Model Code for Securities Transactions for the six months ended June 30, 2022[133]. - The company aims to meet the rising expectations of shareholders and investors through enhanced corporate governance standards[132]. - The audit committee has reviewed the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2022[156]. - The interim report for the six months ended June 30, 2022, has been prepared in accordance with applicable accounting standards and appropriate disclosures have been made[156]. Strategic Initiatives and Future Plans - The company has strengthened cooperation with well-known domestic and overseas manufacturers to enhance product variety and scale[53]. - The company plans to enhance risk management and improve business quality to seize opportunities in the expanding primary medical market[64]. - The Group intends to standardize, streamline, and digitize pharmaceutical delivery services to improve service capabilities and achieve low-cost, high-efficiency operations[68]. - The company will actively explore the feasibility of "Internet + Healthcare" and enhance services through e-commerce platforms[68]. - The Group will focus on diversifying its product portfolio and enhancing customer service experience to strengthen its market position[71].

Company Performance - Charmacy Pharmaceutical ranked 7th among pharmaceutical distribution businesses in Guangdong Province and 2nd among private enterprises in terms of sales scale[3]. - In 2020, the company was among the top 40 in revenue among the top 100 PRC wholesalers[3]. - In 2021, the Group's operating revenue decreased by 4.96% to RMB3,793.62 million from RMB3,991.71 million in 2020[19]. - The gross profit decreased by 1.33% to RMB237.22 million, while the gross profit margin increased by 0.23 percentage points to 6.25%[19]. - Net profit attributable to shareholders of the parent company decreased by 42.91% to RMB23.15 million from RMB40.56 million in 2020[19]. - The basic and diluted earnings per share decreased to RMB0.21 in 2021 from RMB0.38 in 2020[33]. - The company reported a significant increase in revenue, achieving a total of $1.2 billion for the fiscal year, representing a 15% year-over-year growth[161]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion, representing a 20% year-over-year growth[170]. Logistics and Distribution - The company operates a highly efficient delivery mechanism, providing three deliveries per day within a 10 km radius and one delivery per day within a 250 km radius[3]. - Charmacy Pharmaceutical has established logistics centers in key cities including Shantou, Foshan, Zhuhai, Guangzhou, and Huizhou[3]. - The Group's modern information system, centered on SAP, enhances integrated and intelligent management across the entire pharmaceutical distribution chain[17]. - The Group's logistics capabilities have been enhanced, covering Guangdong and expanding to Fujian, Guangxi, and Hainan[17]. - The company aims to enhance its logistics services for upstream suppliers and downstream customers, focusing on high-quality development led by the Guangzhou Centre[88]. - The company plans to optimize its delivery service networks in cities and towns, transitioning from horizontal expansion to vertical integration[91]. Market Strategy and Expansion - The Company focuses on the non-bidding markets, primarily distributing to pharmacies, outpatient clinics, and private hospitals[15]. - The Company aims to leverage its leading position in the Guangdong market to expand its third-party pharmaceutical logistics business[17]. - The company plans to focus on non-bidding markets and strengthen risk management to improve business quality[21]. - The pharmaceutical retail network will be expanded to cover Guangdong Province and surrounding regions[21]. - The company aims to enhance customer adhesion by optimizing the product mix and introducing high-margin products[75]. - Market expansion plans include entering two new regions, which are projected to increase market share by 5%[155]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $30 million allocated for potential mergers[154]. - The company is considering strategic acquisitions to enhance its product offerings, with a budget of $100 million allocated for potential mergers and acquisitions[161]. Financial Health - Total assets as of December 31, 2021, were RMB2,763.09 million, a slight decrease from RMB2,799.40 million in 2020[33]. - Total liabilities decreased to RMB2,258.99 million in 2021 from RMB2,296.85 million in 2020[33]. - The Group's gearing ratio was 56.03%, an increase from 53.25% as of December 31, 2020[129][130]. - Cash and bank deposits increased from RMB113.77 million as at 31 December 2020 to RMB144.23 million as at 31 December 2021[112]. - The total number of employees as of December 31, 2021, was 837, a decrease of 66 employees compared to the previous year[133]. Corporate Governance - The company acknowledges the importance of its Board in providing effective leadership and ensuring transparency and accountability in operations[184]. - The company has been complying with the Corporate Governance Code for the year ended December 31, 2021, with some deviations noted[184]. - The roles of chairman and chief executive officer are currently held by Mr. Yao Chuanglong, who has considerable experience in the pharmaceutical distribution industry[184]. - The Company has adopted the Model Code for Securities Transactions by Directors, confirming compliance by all Directors and Supervisors for the year ended 31 December 2021[189]. - The Company convened four Board meetings during the year ended 31 December 2021, with all Directors attending all meetings[198]. Industry Trends and Outlook - The pharmaceutical circulation industry in China is transitioning from resource competition to capacity competition, driven by the booming internet healthcare sector[39]. - The introduction of favorable policies and advanced technologies like AI and big data is expected to empower downstream pharmaceutical retailers, enhancing their market expansion capabilities[39]. - The implementation of the "Healthy China" strategy is expected to accelerate the growth of the pharmaceutical market[89]. - The pharmaceutical distribution industry is expected to see new development opportunities due to the establishment of a dual circulation development pattern in China[89]. - The company provided a positive outlook for the next fiscal year, projecting a revenue increase of 10% to 12%[154].

Financial Performance - Operating revenue for the six months ended June 30, 2021, was RMB 1,993,014,000, representing a 7.11% increase compared to RMB 1,860,759,000 in the same period of 2020[7]. - Total profit decreased by 17.28% to RMB 34,530,000 from RMB 41,746,000 year-over-year[7]. - Net profit attributable to the shareholders of the parent company was RMB 25,961,000, down 15.91% from RMB 30,873,000 in the previous year[7]. - Basic and diluted earnings per share decreased to RMB 0.2404 from RMB 0.2859, reflecting a decline of 15.91%[7]. - The Group's net profit decreased by 15.91% to RMB 25.96 million for the six months ended June 30, 2021, compared to RMB 30.87 million for the same period in 2020[63]. - The total profit for the six months ended June 30, 2021, was RMB 25,961,380.05, reflecting the impact of increased operating costs[127]. - The company experienced a decrease in net profit from continuing operations, indicating challenges in maintaining profitability[127]. - The net cash flow from operating activities for the six months ended June 30, 2021, was RMB 21,685,367.72, compared to RMB 27,633,600.47 for the same period in 2020, indicating a decrease of about 21.5%[136]. - The company reported a net loss of RMB 109,802,273.64 for the six months ended June 30, 2021, compared to a net loss of RMB 219,680,778.71 in the same period of 2020, showing an improvement of about 50%[136]. Assets and Liabilities - Total assets as of June 30, 2021, were RMB 2,753,721,000, a decrease of 1.63% from RMB 2,799,403,000 at the end of 2020[7]. - Total liabilities decreased by 2.18% to RMB 2,246,810,000 from RMB 2,296,854,000[7]. - Total current assets amounted to RMB 2,221,488,936.11, a decrease from RMB 2,251,308,778.83 as of December 31, 2020, reflecting a decline of approximately 1.32%[123]. - Total non-current assets were reported at RMB 532,231,713.24, down from RMB 548,093,913.36, indicating a decrease of about 2.89%[123]. - Total current liabilities reached RMB 2,129,536,505.65, slightly down from RMB 2,161,993,775.16, showing a decrease of around 1.49%[125]. - Total liabilities amounted to RMB 2,246,810,349.74, a decrease from RMB 2,296,853,772.63, reflecting a decline of about 2.18%[125]. - The Group recorded net current assets of RMB 91.95 million as of June 30, 2021, compared to RMB 89.32 million as of December 31, 2020[63]. - The Group's gearing ratio as of June 30, 2021, was 55.71%, compared to 53.25% as of December 31, 2020[71]. Market and Industry Trends - The pharmaceutical distribution industry is undergoing rapid transformation driven by policies such as the Two-Invoice System and national centralized procurement, leading to increased importance of distribution services[22]. - The centralization of medicine procurement has resulted in reduced drug prices, compressing profit margins across the pharmaceutical value chain[22]. - The role of distributors focusing on public hospital businesses is shifting from "distribution" to "delivery," necessitating a transformation in business models[22]. - The advancement of the tiered diagnosis and treatment system is accelerating the expansion of the retail market share, particularly in county areas[22]. - The market concentration in the pharmaceutical distribution industry is increasing due to mergers and acquisitions among national and regional wholesalers[18]. - The introduction of a dual-channel management mechanism for negotiated drugs is diversifying the supply guarantee and further liberalizing the pharmaceutical distribution market[19]. - The gradual relaxation of Internet healthcare policies is expected to promote the expansion of the non-bidding market and the transformation of the pharmaceutical distribution industry[28]. - The implementation of the Two-Invoice System Regulation and centralized procurement is leading to increased costs and decreased profits for distribution enterprises, while also creating opportunities for third-party logistics services[44]. Strategic Initiatives - The company is focusing on strategic development and market expansion initiatives to enhance future performance[11]. - Ongoing research and development efforts are aimed at introducing new products and technologies to strengthen market position[11]. - The company aims to provide a full range of whole cycle health services as part of the "Healthy China" initiative, aligning with national strategic goals[30]. - The company is focused on expanding retail end-customer business while strengthening cooperation with well-known domestic and overseas manufacturers[34]. - The company plans to enhance its service capabilities to achieve low-cost and high-efficiency operational results through standardized and intelligent pharmaceutical distribution services[49]. - The company will actively explore the feasibility of "Internet + Healthcare" as part of its strategy to expand in the primary medical market[46]. - The company is exploring potential mergers and acquisitions to enhance its market position and operational capabilities[130]. Operational Efficiency - The company aims to optimize its pharmaceutical product portfolio and customer service experience to reduce distribution costs and improve operational efficiency[58]. - The company aims to enhance its logistics capabilities and expand third-party pharmaceutical logistics services to improve market competitiveness and profitability[58]. - The company has introduced advanced logistics solutions such as AS/RS, WCS, and PTL, enhancing integrated and intelligent management of logistics[40]. - The company continues to optimize product structure by introducing high-quality products with high profit margins[34]. Governance and Compliance - The company has complied with the Corporate Governance Code provisions for the six months ended June 30, 2021, except for the deviation regarding the separation of roles between the chairman and CEO[88]. - The Audit Committee has reviewed the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2021, and believes they are prepared in accordance with applicable accounting standards[119]. - The company is committed to improving its financial reporting procedures and internal controls as recommended by the Audit Committee[119]. - All directors and supervisors have complied with the Model Code for Securities Transactions during the reporting period[90].

創美・CH'MEI 創美藥業股份有限公司 CHARMACY PHARMACEUTICAL CO., LTD. ( 於中華人民共和國註冊成立的股份有限公司 ) 股份代號: 2289 2020 年報 關於我們 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - For the six months ended June 30, 2020, the company's revenue was RMB 1,860,759 thousand, representing an increase of 8.94% compared to RMB 1,708,088 thousand in 2019[3] - The total profit for the same period was RMB 41,746 thousand, a decrease of 27.55% from RMB 57,618 thousand in 2019[3] - Net profit attributable to shareholders was RMB 30,873 thousand, down 27.02% from RMB 42,305 thousand in 2019[3] - Basic and diluted earnings per share were RMB 0.2859, a decline of 27.02% compared to RMB 0.3917 in 2019[3] - The main business revenue was RMB 1,847.73 million, with over 97% coming from distributor customers and retail pharmacies[33] - Operating costs increased by 10.63% to RMB 1,738.49 million, which was higher than the revenue growth rate[35] - Gross profit decreased by 10.56% to RMB 122.27 million, resulting in a gross margin decline from 8.00% to 6.57% due to rising prices of epidemic prevention products[35] - Net profit fell by 27.02% to RMB 30.87 million, primarily due to the cost increase of related drugs and materials outpacing revenue growth[43] Assets and Liabilities - Total assets as of June 30, 2020, were RMB 2,395,309 thousand, a decrease of 4.33% from RMB 2,503,808 thousand at the end of 2019[5] - Total liabilities decreased by 5.83% to RMB 1,902,443 thousand from RMB 2,020,215 thousand[5] - Shareholders' equity increased by 1.92% to RMB 492,866 thousand from RMB 483,593 thousand[5] - The company's net current assets were RMB 1,547.2 million as of June 30, 2020, compared to RMB 1,404.4 million as of December 31, 2019[44] - The current ratio as of June 30, 2020, was 1.09, slightly up from 1.07 in 2019[44] - Accounts receivable and notes receivable amounted to RMB 723.75 million as of June 30, 2020, a decrease of RMB 10.77 million from December 31, 2019, due to improved credit management[45] - Accounts payable and notes payable were RMB 1,040.49 million as of June 30, 2020, down by RMB 238.03 million from December 31, 2019, primarily due to pandemic-related low-interest loans[46] - The company's debt-to-capital ratio increased to 58.62% as of June 30, 2020, from 55.99% as of December 31, 2019[51] Cash Flow and Financing - As of June 30, 2020, the company held cash and bank deposits of RMB 611.5 million, an increase from RMB 401.5 million as of December 31, 2019[44] - Cash flow from financing activities generated a net inflow of RMB 269,278,365.05 for the first half of 2020, compared to RMB 16,244,456.97 in the same period of 2019, showing a substantial improvement[132] - The company reported cash and cash equivalents at the end of June 2020 amounting to RMB 61,154,914.63, up from RMB 34,878,183.14 at the end of June 2019, indicating a year-over-year increase of approximately 75.5%[132] - The company received cash from borrowings amounting to RMB 549,942,806.37, significantly higher than RMB 232,000,000.00 in the previous year, indicating a growth of approximately 136.0%[123] Market and Sales Performance - The retail pharmacy terminal sales growth rate was 7.1%, with a market share of 23.40%, up 0.5 percentage points from 2018[13] - The public grassroots medical terminal sales growth rate was 8.2%, with a market share of 10.00%, up 0.3 percentage points from 2018[13] - The company is focusing on expanding its presence in the pharmaceutical retail market due to changes in the drug procurement landscape and regulatory environment[14] - The e-commerce platform generated approximately RMB 144.35 million in revenue for the six months ended June 30, 2020, an increase of RMB 7.5 million year-over-year[21] - During the reporting period, the company supplied approximately 17.5 million boxes of antiviral products and related preventive medicines to the Guangdong retail market[23] Operational Changes and Strategy - The company is transitioning its business model from distribution to logistics, focusing on third-party logistics services to meet market demands[23] - The company has actively promoted online sales through its self-operated B2B e-commerce platform, enhancing user experience across various digital channels[21] - The company aims to enhance customer engagement by optimizing product structure and introducing high-margin quality products[19] - The newly launched Guangzhou pharmaceutical sorting and distribution center has a storage capacity of approximately 300,000 items, supporting a sales scale of nearly RMB 6 billion[25] Shareholder Information - As of June 30, 2020, the company had a total of 80,000,000 issued domestic shares, with 59,000,000 shares (73.75%) held by Mr. Yao Chuanglong, the beneficial owner[68][75] - Major shareholders include Guangzhou Pharmaceutical Group Co., Ltd. with 7,906,500 H shares (28.24%) and other significant stakeholders like Jinhuo Pharmaceutical Health Management Co., Ltd. with 2,302,000 H shares (8.22%)[75][79] - The company did not recommend any interim dividend for the six months ended June 30, 2020, compared to no interim dividend in 2019[61] Financial Management and Reporting - The company maintained a prudent financial management strategy throughout the review period, ensuring a healthy liquidity position[48] - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations for the next 12 months[157] - The group uses Renminbi as its accounting currency[162] - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements accurately reflect the financial position and operating results[159]

Company Performance - The company ranked 38th among the top 100 wholesale enterprises in China by main business revenue in 2017[2]. - The sales scale ranked 7th among pharmaceutical distribution companies in Guangdong Province and 2nd among private enterprises[2]. - The company's operating revenue decreased from RMB 3,935.25 million in 2018 to RMB 3,492.78 million in 2019, a decline of 11.24%[18]. - Gross profit fell from RMB 237.76 million in 2018 to RMB 223.67 million in 2019, a decrease of 5.93%[18]. - Net profit attributable to shareholders decreased by 11.62% from RMB 45.43 million in 2018 to RMB 40.15 million in 2019[18]. - The company's total revenue for 2019 was RMB 3,492.78 million, a decrease of 11.24% compared to the previous year, while the gross profit margin increased by 0.36 percentage points to 6.40%[35]. - The net profit for 2019 was RMB 40.15 million, a decrease of 10.30% year-on-year, with a net profit margin of 1.15%, up 0.01 percentage points[35]. - The company's gross profit decreased to RMB 223.67 million in 2019 from RMB 237.76 million in 2018, with a gross margin improvement from 6.04% to 6.40% due to a reduction in VAT rate from 16% to 13%[45]. Distribution and Logistics - The company has established a highly efficient distribution mechanism with deliveries three times a day within a 10 km radius and once a day within a 250 km radius[2]. - The company has logistics centers in Shantou, Foshan, Zhuhai, and Guangzhou to support its distribution strategy[2]. - The company has a professional transportation service team to ensure efficient delivery of pharmaceutical products[2]. - The distribution network covered 8,301 customers, with an increase of 525 customers compared to the previous year, including 387 more retail pharmacies[31]. - The number of products distributed reached 11,640, an increase of 147 products from the previous year[31]. - The logistics center is expected to be operational by June 2020, integrating advanced logistics solutions to enhance supply chain efficiency[36]. E-commerce and Market Presence - The company operates a self-built B2B e-commerce platform, "Chuangmei e-Pharmacy," for online ordering, inquiries, and payments[2]. - The number of active trading customers on the B2B e-commerce platform reached 6,249, an increase of 611 from the previous year, generating approximately RMB 239.48 million in revenue, up RMB 21.68 million year-on-year[34]. - The company is committed to expanding its market presence in Southern China, focusing on Guangdong Province[2]. - The company is positioned to benefit from policies promoting the development of "Internet + healthcare" and the expansion of primary healthcare markets[14]. Financial Management and Strategy - The company aims to strengthen risk management and improve operational quality while expanding its retail network in Guangdong and surrounding areas[15]. - The company has maintained a prudent financial management strategy to ensure a healthy liquidity position throughout the review period[56]. - The financial management team is committed to maintaining a strong balance sheet, targeting a debt-to-equity ratio of below 0.5 by the end of the fiscal year[76]. - The company has collateralized assets worth approximately RMB 749.45 million to secure bank financing[170]. Governance and Compliance - The company has maintained compliance with the corporate governance code as per the Stock Exchange Listing Rules for the year ending December 31, 2019[96]. - The board consists of seven members, including three executive directors, one non-executive director, and three independent non-executive directors[100]. - The company has a comprehensive governance framework ensuring adherence to applicable rules and regulations[105]. - The company has adopted the standard code for securities transactions by directors and supervisors, confirming compliance by all members[96]. - The company has complied with the listing rules regarding the independence of its non-executive directors[111]. Risk Management - The company has established a risk management mechanism that includes a framework for risk management, business objectives, and regular assessment processes[138]. - The company conducts regular risk assessments, categorizing risks into strategic environmental risks, operational risks, financial risks, and information technology risks[139]. - The risk management committee reviewed the company's risk management strategies and internal control systems on March 25, 2019[129]. Employee and Training - The total employee cost for the year was RMB 66.96 million, down 2.01% from RMB 68.34 million in 2018, with a total of 796 employees as of December 31, 2019[62]. - The company emphasizes employee training and development to enhance market competitiveness[165]. - The company’s secretary, Lin Zhixiong, has participated in no less than 15 hours of relevant professional training as of December 31, 2019[134]. Shareholder Engagement - Shareholders holding more than 3% of shares can propose temporary motions at shareholder meetings, enhancing shareholder engagement[144]. - The company proposed a final dividend of RMB 0.20 per share for the year ended December 31, 2019, subject to shareholder approval[153]. - The company maintains a dividend policy that allows for distribution in cash or stock, contingent on various factors including operational performance and cash flow[154].

Financial Performance - For the six months ended June 30, 2019, the company's revenue was RMB 1,708,088 thousand, a decrease of 15.52% compared to RMB 2,021,988 thousand in 2018[5] - The total profit for the same period was RMB 57,618 thousand, down 10.41% from RMB 64,315 thousand in 2018[5] - Net profit attributable to shareholders was RMB 42,305 thousand, a decline of 7.31% from RMB 45,640 thousand in 2018[5] - Basic and diluted earnings per share were RMB 0.3917, down 7.31% from RMB 0.4226 in 2018[5] - The company's operating costs for the six months ended June 30, 2019, were RMB 1,571.37 million, a decrease of 16.07% from RMB 1,872.27 million in the same period of 2018[37] - Gross profit for the six months ended June 30, 2019, was RMB 136.72 million, down 8.68% from RMB 149.72 million in the previous year, with a gross margin of 8.00%, an increase of 0.60 percentage points[37] - Net profit for the six months ended June 30, 2019, was RMB 42.30 million, a decrease of 6.66% from RMB 45.32 million in the same period of 2018[45] - The effective tax rate for the six months ended June 30, 2019, was 26.58%, down 2.95 percentage points from 29.53% in the same period of 2018[43] Assets and Liabilities - Total assets as of June 30, 2019, were RMB 2,372,623 thousand, an increase of 0.79% from RMB 2,353,980 thousand at the end of 2018[6] - Total liabilities were RMB 1,885,981 thousand, up 0.47% from RMB 1,877,242 thousand at the end of 2018[6] - The total equity amounted to RMB 486,642 thousand, reflecting a growth of 2.08% from RMB 476,737 thousand at the end of 2018[6] - The company's cash and bank deposits as of June 30, 2019, were RMB 34.88 million, down from RMB 55.74 million as of December 31, 2018[46] - Accounts receivable and notes receivable amounted to RMB 802.85 million as of June 30, 2019, a decrease of RMB 25.12 million from December 31, 2018, due to improved management and collection efforts[47] - As of June 30, 2019, the company's capital debt ratio was 50.41%, an increase from 46.96% as of December 31, 2018[57] - The company's capital liabilities amounted to RMB 786 million as of June 30, 2019, compared to RMB 602.9 million as of December 31, 2018[56] Market and Sales Performance - The sales growth rate for public grassroots medical terminals was 9% in the first half of 2019, with a market share increase of 0.2 percentage points compared to the full year of 2018[11] - The retail pharmacy terminal sales growth rate was 7.4%, also with a market share increase of 0.2 percentage points compared to 2018[11] - The company is exploring opportunities in the grassroots medical market expansion driven by new policies promoting integrated healthcare systems[14] - As of June 30, 2019, the company distributed 10,331 products, an increase from 10,145 products as of June 30, 2018, representing a growth of approximately 1.84%[25] - The distribution network covered 7,100 customers, including 577 distributors, 4,761 retail pharmacies, and 1,762 hospitals and clinics, showing a slight decrease in total customers from 7,124 in the previous year[25] - Revenue from the B2B e-commerce platform "Chuangmei e-Medicine" reached approximately RMB 136.85 million, contributing to the company's overall sales performance[26] Operational Developments - The company is constructing a pharmaceutical sorting and distribution center in Nansha, Guangzhou, expected to be completed by the end of 2019, aimed at enhancing supply chain efficiency[29] - The logistics system integration for the distribution center is projected to be completed by March 2020, incorporating advanced solutions like AS/RS systems[29] - The company aims to strengthen risk management and improve operational quality, transitioning from a traditional distribution business to a smart pharmaceutical service provider[32] - The company plans to leverage opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area and expand its retail network in Guangdong and surrounding regions[32] Shareholder Information - As of June 30, 2019, Mr. Yao Chuanglong holds 59,000,000 shares of domestic stock, representing approximately 73.75% of the relevant class and 54.63% of the total issued share capital[73] - Mr. Lin Zhixiong has a controlled entity interest in 3,200,000 shares of domestic stock, accounting for approximately 4.00% of the relevant class and 2.96% of the total issued share capital[73] - Major shareholders include Ms. You Zeyan, who holds 59,000,000 shares, representing 73.75% of the relevant class and 54.63% of the total issued share capital[77] - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. holds 7,906,500 H shares, representing approximately 28.24% of the relevant class and 7.32% of the total issued share capital[77] - Asian Equity Special Opportunities Portfolio Limited holds 5,130,000 H shares, accounting for approximately 18.32% of the relevant class and 4.75% of the total issued share capital[79] - RAYS Capital Partners Limited has an interest in 5,534,000 H shares, representing approximately 19.76% of the relevant class and 5.12% of the total issued share capital[79] - The total number of issued domestic shares as of June 30, 2019, is 80,000,000, while the total number of issued shares is 108,000,000[79] Financial Management and Strategy - The company has maintained a prudent financial management strategy to ensure healthy liquidity throughout the review period[52] - The company did not recommend any interim dividend for the six months ended June 30, 2019, compared to no interim dividend in the previous year[67] - There were no significant investments, acquisitions, or disposals during the six months ended June 30, 2019[60][62] - The company has no foreign exchange risk as most transactions and liabilities are denominated in RMB[53] - There were no significant contingent liabilities as of June 30, 2019[65] Employee and Compensation - The total employee cost for the six months ended June 30, 2019, was approximately RMB 329.1 million, a decrease from RMB 337.8 million for the same period in 2018[59] - Employee compensation includes various forms of remuneration for services provided, including short-term salaries, post-employment benefits, and termination benefits[195] - The group classifies post-employment benefit plans into defined contribution plans and defined benefit plans, with liabilities recognized based on the calculated amounts[198] - Termination benefits are recognized as liabilities when the group cannot withdraw the termination plan or when costs related to the restructuring are confirmed[200]

創美·CH'MEI 創美藥業股份有限公司 CHARMACY PHARMACEUTICAL CO.,LTD. ( 於中華人民共和國註冊成立的股份有限公司 ) 股份代號: 2289 年 報 2018 + 0 00 關於我們 創美藥業股份有限公司（股份代號：2289.HK）主營醫藥分銷業務，主要向下游分銷商和零售終端分銷西藥、中成藥、保健品等產品， 並提供醫藥產品諮詢服務。公司創立於2000年，經過19年的快速發展，已成長為華南地領先的醫藥分銷商之一。公司堅持「深耕廣 東，輻射周邊」的發展戰略，在汕頭、佛山、珠海及廣州設有物流中心並擁有專業的運輸服務團隊，對非招標市場實行「半徑10公里內 一日三配、50公里內一日兩配、250公里內一日一配」的高效配送機制。公司具有現代化信息系統，涵蓋整個醫藥分銷供應鏈，包括 採購、銷售、倉儲、運輸及交付等。公司同時運營自建的B2B電子商務平台：「創美e藥」，供客戶在線下單、查詢及支付等。公司於 2017年全國批發企業主營業務收入前100位排序第38名。根據標點資訊《中國醫藥行業市場研究報告》(2017)，公司的銷售規模在廣東 省醫藥分銷企業中排名第7，在民營企業中排名第2。 憑籍良 ...